Candidate genes, small effects, and the prediction of atherosclerosis

Critical Reviews in Clinical Laboratory Sciences

Volumn 34, Issue 4, 1997, Pages 343-367

  Hegele, Robert A ^a  

^a ST MICHAEL'S HOSPITAL   (Canada)

Author keywords

Genetics; Multifactorial disease; Pathology; Small effects; Weak effects

Indexed keywords

LOW DENSITY LIPOPROTEIN RECEPTOR;

ATHEROGENESIS; ATHEROSCLEROSIS; EPISTASIS; EXPERIMENTAL MODEL; FAMILIAL HYPERCHOLESTEROLEMIA; GENE MUTATION; GENETIC SUSCEPTIBILITY; HEREDITY; HUMAN; PATHOPHYSIOLOGY; PLEIOTROPY; PREDICTION; PRIORITY JOURNAL; REVIEW;

EID: 0030823635     PISSN: 10408363     EISSN: None     Source Type: Journal    
DOI: 10.3109/10408369708998097     Document Type: Review

References (91)

1. Healthy people 2000: National health promotion and disease prevention objectives. US Department of Health and Human Services publication (PHS) 9150212; Hyattsville, MD, 1990.
2. DeBakey, ME. Patterns of atherosclerosis and rates of progression. Atherosclerosis 1978; 3: 1-56.
3. Strong, JP. Atherosclerosis lesions: natural history, risk factors and topography. Arch Pathol Lab Med 1992; 116: 1268-1275.
4. Fuster V, Badimon L, Badimon JJ, et al. The pathogenesis of coronary artery disease and the acute coronary syndromes. N Engl J Med 1992; 326: 242-354.
5. Ross R. The pathogenesis of atherosclerosis: a perspective for the 1990s. Nature 1993; 362: 801-809.
6. Sing, CF, Haviland MB, Templeton AR, et al. Alternative genetic strategy for predicting risk of atherosclerosis. In: Woodford FP, Davignon J Sniderman AD (eds.), Pp. 638-44, Atherosclerosis X, Elsevier Science BV; 1995.
7. Lander ES, Schork, N. Genetic dissection of complex traits. Science 1994; 265: 2037-48.
8. Stary HC, Blankenhorn DH, Chandler AB, et al. A definition of the intima of human arteries and of its atherosclerosis-prone regions. A report from the committee on vascular lesions of the Council on Atherosclerosis, American Heart Association. Arterioscler Thromb 1992; 12: 120-34.
9. Feldman DL, Hoff H Gerrity RG. Immunohistochemical localization of apoprotein B in aortas from hyperlipemic swine: preferential accumulation in lesion-prone areas. Arch Pathol Lab Med 1984; 108: 817-22.
10. Nordestgaard BG, Wooton R Lewis B. Selective retention of VLDL, IDL, and LDL in the arterial intima of genetically hyperlipidemic rabbits in vivo. Molecular size as a determinant of fractional loss from the intima-inner media. Arterioscler Thromb Vasc Biol 1995; 15: 534-42.
11. Gown A, Tsukada T Ross, R. Human atherosclerosis. II. Immunocytochemical analysis of the cellular composition of human atherosclerotic lesions. Am J Pathol 1986; 125: 191-207.
12. Gerrity RG. The role of the monocyte in atherogenesis. I. Transition of blood-borne monocytes into foam cells in fatty lesions. Am J Pathol 1981; 103: 181-190.
13. Steinberg D, Parasarathy S, Carew TE, et al. Beyond cholesterol: modifications of low-density lipoproteins that increase its atherogenicity. N Engl J Med 1989; 320: 915-24.
14. Stary HC. Changes in the cells of athrosclerotic lesions as advanced lesions evolve in coronary arteries of children and young adults. In: Glagov S, Newman WP Schaffer SA, eds. Pp. 93-106. Pathobiology of the human atherosclerotic plaque. New York: Springer, 1990.
15. PDAY Research Group. Natural history of aortic and coronary atherosclerotic lesions in youth. Arterioscler Thromb 1993; 13: 1291-98.
16. Bocan TMA, Schifani TA Guyton JR. Ultrastructure of the human aortic fibrolipid lesion: formation of the atherosclerotic lipid-rich core. Am J Pathol 1986; 123: 413-24.
17. Constantinides P. Plaque ruptures, their genesis and their role in supraplaque thrombosis and atherogenesis. In: Glagov S, Newman WP Schaffer SA, eds. Pp. 393-411. Pathobiology of the human atherosclerotic plaque. New York: Springer, 1990.
18. Mlot C. Chlamydia linked to atherosclerosis. Science 1996; 272: 1422.
19. Biredal-Hansen H. Proteolytic remodeling of extracellular matrix. Curr Opin Cell Biol 1995; 7: 728-35.
20. Hayden MR, Reidy M. Many roads lead to atheroma. Nature Med 1995; 1: 22-3.
21. Hawiger J. Adhesive interactions of the blood cells and the vascular wall. In: Coleman RW, Hirsch J, Marder VJ, eds. Hemostasis and thrombosis: basic principles and clinical practice. Philadelphia: JB Lippincott, 1994: 762-96.
22. Frenette PS, Wagner DD. Adhesion molecules. I. N Engl J Med 1996; 334: 1526-29.
23. Frenette PS, Wagner DD. Adhesion molecules. II. N Engl J Med 1996; 335: 43-5.
24. Vane R, Angaard EE Botting RM. Regulatory functions of the vascular tendothelium. N Engl J Med 1990; 323: 27-36.
25. Vanhoutte PM, Rubanyi G, Miller V, et al. Modulation of vascular smooth muscle contraction by the endothelium. Annu Rev Physiol 1986; 48: 307-20.
26. Yamamoto H, Bosaller C, Cartwright J, et al. Videomicroscopic determination of defective cholinergic arteriolar vasodilation in atherosclerotic rabbit. J Clin Invest 1988; 81: 1752-8.
27. Zeiher AM, Drexler H, Saurbier B, et al. Endothelium-mediated coronary blood flow modulation in humans. Effects of age, atherosclerosis, hypercholesterolemia and hypertension. J Clin Invest 1993; 92: 652-62.
28. Candipan RC, Wamg B-Y, Buitrago R, et al. Regression or progression. Dependency on vascular nitric oxide. Arthioscler Thromb Vasc Biol 1996; 16: 44-50.
29. Berliner JA, Navab M, Fogelman AM, et al. Atherosclerosis: basic mechanisms. Oxidation, inflammation and genetics. Circulation 1995; 91: 2488-96.
30. Ku G, Thomas CA, Akeson AL, et al. Induction of interleukin 1 beta expression from human peripheral blood monocyte-derived macrophages by 9-hydroxyoctadecaoic acid. J Biol Chem 1992; 267: 14183-88.
31. Owens GK. Regulation of differentiation of vascular smooth muscle cells. Physiol Rev 1995; 75: 487-517.
32. Emeson EE, Robert AL. T lymphocytes in aortic and coronary intimas: their potential role in atherogenesis. Am J Pathol 1988; 130: 369-76.
33. Hansson GK, Seifert PS, Olsen G, et al. Immunohistochemical detection of macrophages and T lymphocytes in the atherosclerotic lesions of cholesterol-fed rabbits. Arterioscler Thromb 1991; 11: 745-50.
34. Uretsky BF, Murali S, Reddy S, et al. Development of coronary artery disease in cardiac transplant patients receiving immunosuppressive drug therapy with cyclosporine and prednisone. Circulation 1987; 76: 827-34.
35. Fyfe AI, Qiao JLI Lusis AJ. Immune-deficient mice develop typical atherosclerotic fatty streaks when fed an atherogenic diet. J Clin Invest 1994; 94: 2516-20.
36. Roselaar SE, Schonfeld G Daugherty A. Enhanced development of atherosclerosis in cholesterol-fed rabbits by suppression of cell-mediated immunity. J Clin Invest 1995; 96: 1389-94.
37. Xu Q, Willeit J, Marosi M, et al. Association of serum antibodies to heat shock protein 65 with carotid atherosclerosis. Lancet 1993; 341: 255-9.
38. McMurray HF, Parthasarathy S Steinberg D. Oxidatively modified low-density lipoprotein is a chemoattractant for human T lymphocytes. J Clin Invest 1993; 92: 1004-8.
39. Walden CC, Hegele RA. Apolipoprotein E in hyperlipidemia. Ann Int Med 1994; 120: 1026-36.
40. Black DD. Intestinal lipoprotein metabolism. J Pediatr Gastroenterol Nutr 1995; 20: 125-47.
41. Genest JJ Jr, Martin-Munley SS, McNamara JR, et al. Familial lipoprotein disorders in patients with premature coronary artery disease. Circulation 1992; 85: 2025-33.
42. Scanu AM, Fless GM. Lipoprotein(a): heterogeneity and biological relevance. J Clin Invest 1990; 85: 1709-15.
43. Breslow JL. Familial disorders of high-density lipoprotein metabolism. In: Scriver CR, Beaudet AL Sly WS Valle D (eds.). Pp. 1251-66. The metabolic basis of inherited disease. 6th ed., New York: McGraw-Hill, 1989.
44. Rose G. Familial patterns in ischemic heart disease. Br J Prev Soc Med 1964; 18: 75-80.
45. Marenberg ME, Risch N, Berman LF, et al. Genetic susceptibility to death from coronary heart disease in a study of twins. N Engl J Med 1994; 330: 1041-46.
46. Dammerman M, Breslow JL. Genetic basis for lipoprotein disorders. Circulation 1995; 91: 505-12.
47. Davignon J. Roy M. Familial hypercholesterolemia in French Canadians: taking advantage of a "founder effect". Am J Cardiol 1993; 72: 6D-10D.
48. Mehrabian M, Lusis AJ. Genetic markers for studies of atherosclerosis and related risk factors. In: Lusis AJ, Rotter JI Sparkes RS, eds. Molecular genetics of coronary artery disease: candidate genes and processes in atherosclerosis. Pp. 363-418. Monograph in Human Genetics. Basel: Karger, 1992.
49. Acton S, Rigotti A, Landsculz KT, et al. Identification of scavenger receptor SRBI as a high-density lipoprotein receptor. Science 1996; 271: 518-20.
50. Brown GB, Zhao X-Q, Sacco D, et al. Lipid-lowering plaque regression. Circulation 1993; 87: 1781-91.
51. Simvastain Survival Study Group. Randomized trial of cholesterol lowering in 4444 pateints with coronary heart disease: the Scandinavian simvastatin survival study. Lancet 1994; 344: 1383-89.
52. Williams RR, Hasstedt SJ, Wilson DE, et al. Evidence that men with familial hypercholesterolemia can avoid early death. An analysis of 77 gene carriers in four Utah pedigrees. JAMA 1986; 255: 219-24.
53. Hegele RA, Emi M, Wu LL, et al. Clinical application of deoxyribonulceic acid markers in Utah family with hypercholesterolemia. Am J Cardiol 1989; 63: 109-12.
54. Emi M, Hegele RA, Hopkins PN, et al. Effects of three genetic loci in a family with multiple lipoprotein phenotypes. Arterioscler Thromb 1991; 11: 1349-55.
55. Hopkins PN, Wu LL, Schumacher MC, et al. Type III dyslipoproteinemia in patients heterozygous for familial hypercholesterolemia and apolipoprotein E2. Evidence for a gene-gene interaction. Arterioscler Thromb 1991; 11: 1137-46.
56. Hegele RA, Breckenridge WC, Cox DW, et al. Interaction between variant apolipoproteins CII and E that affects plasma lipoproteins. Arterioscler Thromb 1991; 11: 1303-09.
57. Meade TW, Mellows S, Brozovic M, et al. Hemostatic function and ischemic heart disease: principal results of the Northwick Park Heart Study. Lancet 1986; 2: 533-7.
58. Bernardi F, Marchetti G, Pinotti, et al. Factor VII gene polymorphisms contribute about one third of the factor VII variation in plasma. Arterioscler Thromb Vasc Biol 1996; 16: 72-6.
59. Hoffman CJ, Lawson WE, Miller RH, et al. Correlation of vitamin K-dependent clotting factors with cholesterol and triglycerides in healthy young adults. Arterioscler Thromb 1994; 14: 1737-40.
60. Humphries SE, Lane A, Green FR, et al. Factor VII coagulant activity and antigen levels in healthy men are determined by interaction between factor VII genotype and plasma triglyceride concentration. Arterioscler Thromb 1994; 14: 193-8.
61. Saha N, Liu Y, Heng CK, et al. Association of factor VII genotype with plasma factor VII activity and antigen levels in healthy Indian adults and interaction with triglycerides. Arterioscler Thromb 1994; 14: 1923-27.
62. Li WW, Dammerman MM, Smith JD, et al. Common genetic variation in the promoter of the human apo CIII gene abolishes regulation by insulin and may contribute to hypertriglyceridemia. J Clin Invest 1995; 96: 2601-05.
63. Reaven GM. Role of insulin resistance in human disease: Banting lecture. Diabetes 1988; 37: 1595-607.
64. Mitchell BD, Kammerer CM, Mahaney MC, et al. Genetic analysis of the IRS. Pleiotropic effects of genes influencing insulin levels on plasma lipoprotein and obesity measures. Arterioscler Thromb Vasc Biol 1996; 16: 281-88.
65. Reaven GM, Lithell H Landsberg L. Hypertension and associated metabolic abnormalities: the role of insulin and the sympathoadrenal system. N Engl J Med 1996; 334: 374-81.
66. Falkner B, Kushner H, Tulenko T, et al. Insulin sensitivity, lipids and blood pressure in young American blacks. Arterioscler Thromb Vasc Biol 1996; 15: 1798-1804.
67. Lewis GF, Uffelman KD, Szeto LW, et al. Interaction between free fatty acids and insulin in the acute control of very low-density production in humans. J Clin Invest 1995; 95: 158-66.
68. Simon JA, Fong J Bernert JT Jr. Serum fatty acids and blood pressure. Hypertension 1996; 27: 303-7.
69. Mitchell BD, Kammerer CM, O'Connell P, et al. Evidence for linkage of postchallenge insulin levels with intestinal fatty acid binding protein (FABP2) in Mexican-Americans. Diabetes 1995; 44: 1046-53.
70. Baier LJ, Sacchettini JC, Knowler WC, et al. An amino acid substitution in the human intestinal fatty acid binding, increased fat oxidation and insulin resistance. J Clin Invest 1995; 95: 1281-7.
71. Hegele RA, Evans AJ, Tu L, et al. A gene-gender interaction affecting plasma lipoproteins in a genetic isolate. Arterioscler Thromb 1994; 14: 671-8.
72. Hegele RA, Brunt JH Connelly PW. Multiple genetic determinants of variation of plasma lipoproteins in Alberta Hutterites. Arterioscler Thomb Vasc Biol 1995; 15: 861-71.
73. Hegele RA, Brunt JH Connelly PW. A polymorphism of the angiotensinogen gene associated with variation in blood pressure in a genetic isolate. Circulation 1994; 90: 2207-12.
74. Regele RA, Brunt JH Connelly PW. Genetic variation on chromosome 1 associated with variation in body fat distribution in men. Circulation 1995; 92: 1089-93.
75. Cohen JC, Wang Z, Grundy SM, et al. Variation at the hepatic lipase and apolipoprotein AI/CIII/AIV loci is a major cause of genetically determined variation in plasma HDL cholesterol levels. J Clin Invest 1994; 94: 2377-84.
76. Haseman JK, Elston RC. The investigation of linkage between a quantitative trait and a marker locus. Behav Genet 1970; 2: 2-19.
77. Mahaney MC, Blangero J, Rainwater DL, et al. A major locus influencing plasma high-density lipoprotein cholesterol levels in the San Antonio Family Heart Study. Arterioscter Thromb Vasc Biol 1995; 15: 1730-39.
78. Bu, X, Warden CH, Xia Y-R, et al. Linkage analysis of the genetic determinants of high-density lipoprotein concentrations and composition: evidence of involvement of the apolipoprotein A-II and cholesteryl ester transfer protein loci. Hum Genet 1994; 93: 639-48.
79. Puffenberger EG, Kauffman ER, Bolk S, et al. Identity by descent and association mapping of a recessive gene for Hirschprung disease on human chromosome 13q22. Hum Mol Genet 1994; 3: 1217-26.
80. Chung E, Curtis D, Chen G, et al. Genetic evidence for the neuronal nitric oxide synthase gene (NOS1) as a susceptibility locus for infantile pyloric stenosis. Am J Hum Genet 1996; 58: 363-70.
81. Stafforini DM, Satoh K, Atkinson DL, et al. Platelet activating factor acetylhydrolase deficiency. A missense mutation near the active site of an antiinflammatory phospholipase. J Clin Invest 1996; 97: 2784-91.
82. Mackness MI, Mackness B, Durrington PN, et al. Paraoxonase: biochemistry, genetic and relationship to plasma lipoproteins. Curr Opin Lipidol 1996; 7: 69-76.
83. Hegele RA, Brunt JH Connelly PW. A polymorphism of the paraoxonase gene associated with variation in plasma lipoproteins in Alberta Hutterites. Arterioscler Thromb Vase Biol 1995; 15: 89-95.
84. Ruiz J, Blanche H, James RW, et al. Gln-Arg 192 polymorphism of paraoxonase and coronary heart disease in type 2 diabetes. Lancet 1995; 346: 869-72.
85. Serrato M, Marian AJ. A variant of human paraoxonase/arylesterase (HUMPONA) gene is a risk factor for coronary artery disease. J Clin Invest 1995; 36: 3005-8.
86. Purcell-Huynhc, Weinrab A, Castellani LW, et al. Genetic factors in lipoprotein metabolism. Analysis of a genetic cross between inbred mouse strains NZB/ BINJ and SM/J using a complete linkage map approach. J Clin Invest 1995; 96: 1845-58.
87. Reue K, Doolittle MH. Naturally occurring mutations in mice affecting lipid transport and metabolism. J Lipid Res 1996; 37: 1387-405.
88. Welch CL, Xia Y-R, Scheeler I, et al. Genetic regulation of cholesterol homeostasis: chromosomal organization of candidate genes. J Lipid Res 1996; 37: 1406-21.
89. Breslow JL. Mouse models of atherosclerosis. Science 1996; 272: 685-8.
90. Breslow JL. Insights into lipoprotein metabolism from studies in transgenic mice. Annu Rev Physiol 1994; 56: 797-810.
91. Wynshaw-Boris A. Model mice and human disease. Nature Genet 1996; 13: 259-60.